Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2′F-RNA Aptamers

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) has evolved a number of strategies to resist current antiretroviral drugs and the selection pressures of humoral and cellular adaptive immunity. For example, R5 strains, which use the CCR5 coreceptor for entry and are the dominant viral phenotype for HIV-1 transmission and AIDS pathogenesis, are relatively resistant to neutralization by antibodies, as are other clinical isolates. In order to overcome these adaptations, we raised nucleic acid aptamers to the SU glycoprotein (gp120) of the R5 strain, HIV-1Ba-L. These not only bound gp120 with high affinity but also neutralized HIV-1 infectivity in human peripheral blood mononuclear cells (PBMCs) by more than 1,000-fold. Furthermore, these aptamers were able to neutralize the infectivity of R5 clinical isolates of HIV-1 derived from group M (subtypes A, C, D, E, and F) and group O. One aptamer defined a site on gp120 that overlaps partially with the conserved, chemokine receptor-binding, CD4-induced epitope recognized by monoclonal antibody 17b. In contrast to the antibody, the site is accessible to aptamer in the absence of CD4 binding. Neutralizing aptamers such as this could be exploited to provide leads in developing alternative, efficacious anti-HIV-1 drugs and lead to a deeper understanding of the molecular interactions between the virus and its host cell.

[1]  D. Markovitz,et al.  Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. , 1986, JAMA.

[2]  A. Trkola,et al.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  W. James,et al.  Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120. , 2002, Biochemical and biophysical research communications.

[4]  M. Girard,et al.  A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody , 1994, Journal of virology.

[5]  T. Fitzwater,et al.  Potent 2′-amino-, and 2′-fluoro-2′- deoxyribonucleotide RNA inhibitors of keratinocyte growth factor , 1997, Nature Biotechnology.

[6]  J. Sodroski,et al.  Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. , 2000, AIDS research and human retroviruses.

[7]  D. Mosier,et al.  Macrophage-tropic HIV: critical for AIDS pathogenesis? , 1994, Immunology today.

[8]  L. Pearl,et al.  Characterization of HIV‐1 neutralization escape mutants , 1989, AIDS.

[9]  P. Illei,et al.  Definition of the range and distribution of human immunodeficiency virus macrophage tropism using PCR-based infectivity measurements. , 1994, The Journal of general virology.

[10]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[11]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[12]  Nigel Bosworth,et al.  Scintillation proximity assay , 1989, Nature.

[13]  A. Trkola,et al.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.

[14]  T. Fitzwater,et al.  A SELEX primer. , 1996, Methods in enzymology.

[15]  J. Gershoni,et al.  HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  R. Laufs,et al.  Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. , 2001, AIDS.

[17]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[18]  Michael Emerman,et al.  Single amino-acid changes in HIV envelope affect viral tropism and receptor binding , 1989, Nature.

[19]  P. Vernazza,et al.  Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.

[20]  B. Chesebro,et al.  Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages , 1991, Journal of virology.

[21]  Andreas D. Baxevanis,et al.  The Molecular Biology Database Collection: 2002 update , 2002, Nucleic Acids Res..

[22]  H. Gendelman,et al.  The macrophage in the persistence and pathogenesis of HIV infection. , 1989, AIDS.

[23]  J. Moore,et al.  Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. , 1990, AIDS.

[24]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[25]  Eric Hunter,et al.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.

[26]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[27]  R. Karlsson,et al.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.

[28]  D R Burton,et al.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Moore,et al.  HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.

[30]  W. James,et al.  A rat CD4 mutant containing the gp120-binding site mediates human immunodeficiency virus type 1 infection , 1993, The Journal of experimental medicine.

[31]  L. Montaner,et al.  PCR analysis of HIV1 infection of macrophages: virus entry is CD4-dependent. , 1993, Research in virology.

[32]  J. Sodroski,et al.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. , 1987, Science.

[33]  L. King,et al.  The Baculovirus Expression System , 1992 .

[34]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[35]  G. Gao,et al.  Macrophage-Tropic HIV Induces and Exploits Dendritic Cell Chemotaxis , 2000, The Journal of experimental medicine.

[36]  J. Sodroski,et al.  Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. , 1998, Virology.

[37]  J. Sodroski,et al.  CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization , 1998, Journal of Virology.

[38]  W A Hendrickson,et al.  Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. , 2000, Structure.

[39]  P S Kim,et al.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Burke,et al.  Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes , 1988, The Journal of experimental medicine.

[41]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[42]  K. Murthy,et al.  Prevention of HIV infection by passive immunization with HIV immunoglobulin. , 1991, AIDS research and human retroviruses.

[43]  A. Cann,et al.  Molecular determinants of the V3 loop of human immunodeficiency virus type 1 glycoprotein gp120 responsible for controlling cell tropism. , 1994, The Journal of general virology.

[44]  G. Marius Clore,et al.  Design of a Novel Peptide Inhibitor of HIV Fusion That Disrupts the Internal Trimeric Coiled-coil of gp41* , 2002, The Journal of Biological Chemistry.

[45]  J. Sodroski,et al.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding , 1995, Journal of virology.

[46]  Pascale Romby,et al.  High affinity nucleic acid aptamers for streptavidin incorporated into bi-specific capture ligands. , 2002, Nucleic acids research.

[47]  Neff Walker,et al.  The global impact of HIV/AIDS , 2001, Nature.

[48]  D. Montefiori,et al.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.

[49]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[50]  Stuart L. Schreiber,et al.  Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements , 1999, Nature Structural Biology.

[51]  Ying Sun,et al.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.

[52]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[53]  D. Dunigan,et al.  The Baculovirus Expression System: A Laboratory Guide , 1992 .

[54]  J. Hansen,et al.  Autologous HIV‐1 Neutralizing Antibodies: Emergence of Neutralization‐Resistant Escape Virus and Subsequent Development of Escape Virus Neutralizing Antibodies , 1992, Journal of acquired immune deficiency syndromes.

[55]  A. Barclay,et al.  Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. , 1998, Journal of immunology.